http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022076528-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52bfa56b53d26e6922a75b98b0fefaf0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-165 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-541 |
| filingDate | 2021-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_237dfef6c341bb3bdd3e61eff702baf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a402108738d370c262786c12c16261 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f10b0ca9a8e554d3532cebf911c6572d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_989ad60d524ea27ef837aa445515097e |
| publicationDate | 2022-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022076528-A1 |
| titleOfInvention | Dual-antigen elisa for epidemiological and population studies of resistance and sensitivity to covid-19 |
| abstract | Systems, kits and methods for identifying an individual with an adaptive response to SARS-CoV-2 virus. The methods may comprise: 1) contacting a blood serum or blood plasma specimen of the individual with each of two antigens immobilized on a solid support, a first antigen and a second antigen, wherein the first antigen comprises a first SARS-CoV-2 protein or an immunogenic fragment therefore, and the second antigen comprises a second SARS-CoV-2 protein or an immunogenic fragment therefore; 2) capturing antibodies specific to the each of the two antigens from a blood serum or blood plasma specimen into complexes with each of the two antigens; 3) detecting first complexes comprising the first antigen and captured antibodies and detecting second complexes comprising the second antigen and captured antibodies; and 4) reporting the individual as having an adaptive response to SARS-CoV-2 virus after both the first and the second complexes have been detected. |
| priorityDate | 2020-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.